These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 33633058)

  • 21. Research Techniques Made Simple: Sample SizeĀ Estimation and Power Calculation.
    Schmidt SAJ; Lo S; Hollestein LM
    J Invest Dermatol; 2018 Aug; 138(8):1678-1682. PubMed ID: 30032783
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Concepts in sample size determination.
    Rao UK
    Indian J Dent Res; 2012; 23(5):660-4. PubMed ID: 23422614
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Statistical power and sample size calculations: A primer for pediatric surgeons.
    Staffa SJ; Zurakowski D
    J Pediatr Surg; 2020 Jul; 55(7):1173-1179. PubMed ID: 31155391
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Not significant--what now?].
    Gerss J
    Zentralbl Gynakol; 2006 Dec; 128(6):307-10. PubMed ID: 17213967
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bayesian Hodges-Lehmann tests for statistical equivalence in the two-sample setting: Power analysis, type I error rates and equivalence boundary selection in biomedical research.
    Kelter R
    BMC Med Res Methodol; 2021 Aug; 21(1):171. PubMed ID: 34404344
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical trials with nested subgroups: Analysis, sample size determination and internal pilot studies.
    Placzek M; Friede T
    Stat Methods Med Res; 2018 Nov; 27(11):3286-3303. PubMed ID: 29298604
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized Controlled Trials 6: Determining the Sample Size and Power for Clinical Trials and Cohort Studies.
    Greene T
    Methods Mol Biol; 2021; 2249():281-305. PubMed ID: 33871850
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sample size adjustment based on promising interim results and its application in confirmatory clinical trials.
    Chen YH; Li C; Lan KK
    Clin Trials; 2015 Dec; 12(6):584-95. PubMed ID: 26195615
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The cost of large numbers of hypothesis tests on power, effect size and sample size.
    Lazzeroni LC; Ray A
    Mol Psychiatry; 2012 Jan; 17(1):108-14. PubMed ID: 21060308
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Variable criteria sequential stopping rule: Validity and power with repeated measures ANOVA, multiple correlation, MANOVA and relation to Chi-square distribution.
    Fitts DA
    Behav Res Methods; 2018 Oct; 50(5):1988-2003. PubMed ID: 28936614
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tutorial: Small-N Power Analysis.
    Kyonka EGE
    Perspect Behav Sci; 2019 Mar; 42(1):133-152. PubMed ID: 31976425
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Maximum information designs.
    Lachin JM
    Clin Trials; 2005; 2(5):453-64. PubMed ID: 16315649
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sample size recalculation using conditional power.
    Denne JS
    Stat Med; 2001 Sep 15-30; 20(17-18):2645-60. PubMed ID: 11523074
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Decision qualities of Bayes factor and p value-based hypothesis testing.
    Jeon M; De Boeck P
    Psychol Methods; 2017 Jun; 22(2):340-360. PubMed ID: 28594227
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Setting an optimal Ī± that minimizes errors in null hypothesis significance tests.
    Mudge JF; Baker LF; Edge CB; Houlahan JE
    PLoS One; 2012; 7(2):e32734. PubMed ID: 22389720
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The importance of a priori sample size estimation in strength and conditioning research.
    Beck TW
    J Strength Cond Res; 2013 Aug; 27(8):2323-37. PubMed ID: 23880657
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sample size determination and power analysis using the G*Power software.
    Kang H
    J Educ Eval Health Prof; 2021; 18():17. PubMed ID: 34325496
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An internal pilot design for prospective cancer screening trials with unknown disease prevalence.
    Brinton JT; Ringham BM; Glueck DH
    Trials; 2015 Oct; 16():458. PubMed ID: 26463684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A confidence function-based posterior probability design for phase II cancer trials.
    Shan M
    Pharm Stat; 2021 May; 20(3):485-498. PubMed ID: 33336856
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.